Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data

Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA therapies and its lead asset, zerlasiran, targets Lp(a) to treat atherosclerotic cardiovascular disease, the analyst tells investors in a research note. The firm says that although Silence demonstrated encouraging Lp(a) reductions, its time-averaged data along with Lp(a) levels between doses “look undifferentiated.” Further, zerlasiran’s waning effects between doses suggest that more frequent dosing may be necessary and differentiation by less frequent dosing may not be possible, contends Goldman. The firm thinks the shares could remain range bound.